Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer

26 Feb 2022

Abstract excerpt

The Myc family of transcription factors are involved in the development and progression of numerous cancers, including prostate cancer (PCa). Under the pressure of androgen receptor (AR)-directed therapies resistance can occur, leading to the lethal form of PCa known as neuroendocrine prostate cancer (NEPC), characterized among other features by N-Myc overexpression. There are no clinically approved treatments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35269731
DOI: 10.3390/ijms23052588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate CancerPMID 35269731Read ↗

KDM4A promotes the progression of neuroendocrine prostate cancerSemantic proximity Read ↗

A novel inhibitor L755507 efficiently blocks c-Myc–MAX heterodimerization and induces apoptosis in cancer cellsSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent CancersSemantic proximity Read ↗

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive reviewSemantic proximity Read ↗

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.Semantic proximity Read ↗

Emerging Developments in ETS-Positive Prostate Cancer TherapySemantic proximity Read ↗

Targeting the KDM4B–AR–c‐Myc axis promotes sensitivity to androgen receptor‐targeted therapy in advanced prostate cancerSemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domainSemantic proximity Read ↗

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Turning Up the Heat on MYC: Progress in Small-Molecule InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.